ELCC 2022 | Promising results for advanced thymic tumors

Nicolas Girard, MD, PhD, Institut Curie, Paris, France, talks on promising results in systemic therapies for patients with advanced or metastatic thymic tumors. The current first-line standard of care (SOC) is chemotherapy, with response rates in patients with thymomas or thymic carcinomas of 30-40%. Following disease progression, therapies including antiangiogenics and immunotherapy have demonstrated clinical benefit for this patients population in recent clinical trials, including a progression-free survival (PFS) rate of approximately 40%. This interview took place during the virtual European Lung Cancer Congress 2022.